About the Company
Catalyst is a clinical-stage biopharmaceutical company leveraging exceptional science to discover and develop essential medicines.
Catalyst is focused on creating and commercializing novel medicines to address serious medical conditions for patients who need new or better treatment options.
Engineered proteases can efficiently initiate or regulate protease-driven biological cascades and can act on hundreds to thousands of target molecules.
While our scientific approach is singularly focused on protease therapeutic agents, our opportunities are many. Learn more about Our Pipeline.
A protease is an enzyme that cleaves target proteins. Learn more about Our Science.
Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
— Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end — — Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-end– SOUTH SAN FRANCISCO, Calif., Nov. 02,...
Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors
Senior pharmaceutical executive with extensive experience in hematology and hemophilia Led Baxalta’s Global Blood Disorders Franchise within the Hematology Division SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused...
Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases
Collaboration aims to develop best-in-class anti-C3 intravitreal products with quarterly dosing frequency and better potency C3 is a clinically validated target in dry age-related macular degeneration, a large multi-billion-dollar market with no approved therapies SOUTH SAN FRANCISCO, Calif. and...
Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B
— Orphan drug designation provides marketing exclusivity if approved by FDA — SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for...